Peg‐interferon and ribavirin treatment in <scp>HIV</scp>/<scp>HCV</scp> co‐infected patients in Thailand: efficacy, safety and pharmacokinetics

Smolders, Elise J; Thammajaruk, N.; Kanter, Clara T. M. M. de; Colbers, Angela; Chaiyahong, Prachya; Cuprasitrut, T.; Chittmittraprap, S.; Apornpong, Tanakorn; Khemnark, Suparat; Tangkijvanich, Pisit; Burger, David M.; Avihingsanon, Anchalee

doi:10.1111/tmi.13027

Cited by 5 publications

(4 citation statements)

References 24 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although they are not listed in the drug labels, they indicate the possible adverse events in the treatment of ribavirin-interferon combination. A prospective multicenter study in Thailand [ 17 ] showed that a patient with HCV and HIV had severe hemoptysis after treatment with ribavirin-interferon combination and was consistent with our signal detection results. ADEs cannot be easily detected in studies conducted before the drug reaches the market; new adverse reports may appear after the drug is marketed, while the update of the drug label is lagging behind.…”

Section: Discussionsupporting

confidence: 90%

“…In a multicenter trial [ 16 ], one patient stopped treatment at the 42nd week of treatment due to the decrease of platelet to 45000/mm 3 . In another study [ 17 ], a case of death due to combined treatment was reported. At the start of treatment, the patient already had a rather low platelet count; the platelet further drops after the combined treatment and finally leads to death.…”

Section: Discussionmentioning

confidence: 99%

“…Depression was a signal with a higher number of reports and PRR, ROR, and IC values in the nervous system. At present, studies have confirmed that patients undergoing treatment of ribavirin-interferon combination will increase the risk of diseases such as depression and anxiety [ 17 , 18 ]. In the face of an outbreak, patients with COVID-19 may be lonely, anxious, and have insomnia and are more likely not to cooperate with the treatment due to fear of the disease.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy

Shan

Hong

Zhu

et al. 2020

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Purpose. We aimed to analyze and evaluate the safety signals of ribavirin-interferon combination through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS), so as to provide reference for the rationale use of these agents in the management of relevant toxicities emerging in patients with novel coronavirus pneumonia (COVID-19). Methods. Reports to the FAERS from 1 January 2004 to 8 March 2020 were analyzed. The proportion of report ratio (PRR), reporting odds ratio (ROR), and Bayesian confidence interval progressive neural network (BCPNN) method were used to detect the safety signals. Results. A total of 55 safety signals were detected from the top 250 adverse event reactions in 2200 reports, but 19 signals were not included in the drug labels. All the detected adverse event reactions were associated with 13 System Organ Classes (SOC), such as gastrointestinal, blood and lymph, hepatobiliary, endocrine, and various nervous systems. The most frequent adverse events were analyzed, and the results showed that females were more likely to suffer from anemia, vomiting, neutropenia, diarrhea, and insomnia. Conclusion. The ADE (adverse drug event) signal detection based on FAERS is helpful to clarify the potential adverse events related to ribavirin-interferon combination for novel coronavirus therapy; clinicians should pay attention to the adverse reactions of gastrointestinal and blood systems, closely monitor the fluctuations of the platelet count, and carry out necessary mental health interventions to avoid serious adverse events.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy

Shan

Hong

Zhu

et al. 2020

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…The predominance of subtype 1b corroborates earlier reports on the subtype as the predominant HCV subtype across the globe [4,11]. In addition to the cases of dual 'mixed' genotype infections identified in this study, several cases involving a mixture of more than two genotypes and/or subtypes in patients were reported in Indonesia, Vietnam, and Thailand [28,80,93]. Expectedly, such infected individuals would require more than the usual combinations of the available HCV drugs for optimal treatment outcomes.…”

Section: Plos Onesupporting

confidence: 91%

Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Known for its high genetic diversity and variation in genotypic presence in different regions of the world, hepatitis C virus (HCV) is estimated to infect about 71 million people globally. Selection of an appropriate therapeutic regimen largely depends on the identification of the genotype responsible for the infection. This systematic review and meta-analysis was conducted to provide a comprehensive view of HCV genotype and subtype distribution in Southeast Asia (SEA). The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA). We searched five databases without year and language restrictions. Data from 90 eligible studies involving 15,089 genotypes and 9,646 subtypes representing 10 SEA countries were analyzed. The pooled estimates showed that genotype 1 (46.8%) [95% CI, 43.2–50.4; I2 = 92.77%; p < 0.001] was the most dominant HCV genotype in the region, followed by genotype 3 (23.1%) [95% CI, 19.4–27.2; I2 = 93.03%; p < 0.001], genotype 6 (16.5%) [95% CI, 13.8–19.6], genotype 2 (4.6%) [95% CI, 3.5–5.9], genotype 4 (1.1%) [95% CI, 0.7–1.5] and genotype 5 (0.8%) [95% CI, 0.4–1.3]. Philippines had the highest prevalence of genotypes 1 and 2. Genotype 6 became more prevalent after year 2000. Over 40 different subtypes were identified, with subtypes 1b (26.3%), 1a (21.3%), and 3a (14.3%) being the most prevalent of all the reported subtypes. Although on a global scale, genotype 6 is considered highly prevalent in SEA, evidence from this study reveals that it is the third most prevalent genotype within the region.

show abstract

A novel recyclable nano-adsorbent for enhanced oil recovery with efficient removal of Ca2+ and Cr6+ from oilfield wastewater

Dai

Wang

et al. 2022

Korean J. Chem. Eng.

View full text Add to dashboard Cite

Peg‐interferon and ribavirin treatment in HIV/HCV co‐infected patients in Thailand: efficacy, safety and pharmacokinetics

Cited by 5 publications

References 24 publications

Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy

Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy

Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis

A novel recyclable nano-adsorbent for enhanced oil recovery with efficient removal of Ca2+ and Cr6+ from oilfield wastewater

Contact Info

Product

Resources

About